Sotera Health Company

SHC Healthcare Diagnostics & Research

Sotera Health Company’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 5.74% from fiscal 2024.

Revenue
+4.36%
EPS
+20.1%
Free cash flow
+65.0%
Total debt
+0.14%

Quarter to September 2026, against a year earlier

15.77 0.10 −0.63%
Market cap
$4.5B
P/E
26.3×
Fwd P/E
26.4×
Dividend yield
—
F-score
7/9
Altman Z
1.76
Beneish M
−2.75
Dividend safety
n/a

Sotera Health Company (SHC) P/E ratio

Alert me on P/E ratio

As of 5 November 2026, Sotera Health Company (SHC) trades at a P/E ratio of 26.3×. Over the past ten years it has ranged from 0.0× (December 2023) to 5,185× (December 2020); the current reading is higher than 30% of that period. That is below the Diagnostics & Research industry median of 34.5× and in line with the Healthcare sector median of 25.2×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 65.3× (28.36%)
FY2024 91.2× (1.99%)
FY2023 93.1× —
FY2022 0.0× —
FY2021 56.1× —
FY2020 0.0× —
FY2019 4,648× 0.00%
FY2018 4,648× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 30.6× (1.73%)
Jun 2026 31.1× (10.97%)
Mar 2026 35.0× (46.47%)
Dec 2025 65.3× (21.09%)
24 more quarters

Against its own ten years

Low 0.0× High 5,185×
Ten-year median 50.3×
Current reading's percentile 7

P/E ratio against peers

Company P/E ratio
RDNT RadNet, Inc. compare n/m
NEO NeoGenomics, Inc. compare n/m
GRAL GRAIL, Inc. compare n/m
ADPT Adaptive Biotechnologies Corporation compare n/m
VCYT Veracyte, Inc. compare 15.2×
QGEN QIAGEN N.V. compare 26.1×
SHC Sotera Health Company 26.3×
CDNA CareDx, Inc. compare 30.9×
BLLN BillionToOne, Inc. compare 88.7×
Diagnostics & Research industry median 34.5×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on SHC